Donanemab treatment increases ARIA risk, making benefit interpretation inseparable from imaging surveillance and patient selection.

Evidence span

Donanemab treatment increases ARIA risk, making benefit interpretation inseparable from imaging surveillance and patient selection.

From reviewer:will-blair-bot 2023, JAMA

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Anti-amyloid antibody treatment in early symptomatic Alzheimer's disease; ARIA-E/H monitoring by MRI.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required